Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 263805, 8 pages
http://dx.doi.org/10.1155/2013/263805
Research Article

Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study

1D2L Pharma Research Centre, Bangalore 560 037, India
2NICS, Seoul 135-763, Republic of Korea
3Korea Polytechnic University, Siheung-Si 429-793, Republic of Korea
4Research and Development Centre, Natural Remedies, Plot No.5B, Veerasandra Indl. Area, 19th K.M. Stone, Hosur Road, Electronic City, Bangalore, Karnataka 560 100, India
5Anasuya Ayurveda Centre, Bangalore 560 050, India

Received 3 December 2012; Revised 11 February 2013; Accepted 11 February 2013

Academic Editor: Byung-Cheul Shin

Copyright © 2013 Sreenivasulu Puram et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A randomized, double blind placebo controlled study was conducted to evaluate the efficacy of GutGard (root extract of Glycyrrhiza glabra) in the management of Helicobacter pylori (H. pylori) gastric load. Participants diagnosed with H. pylori infection were randomly assigned to two groups to orally receive 150 mg of GutGard ( ) or placebo ( ) once daily for 60 days. H. pylori infection was assessed using 13C-urea breath test (13C-UBT) at days 0, 30, and 60. Stool Antigen test (HpSA) was also performed on days 0, 30, and 60. Repeated measures of analysis of variance (RMANOVA), chi-square, and Fisher's exact probability tests were used to compare the treatment outcomes. A significant interaction effect between group and time ( ) and significant difference in mean Delta Over Baseline (DOB) values between GutGard ( ) and placebo ( ) treated groups after intervention period were observed. On day 60, the results of HpSA test were negative in 28 subjects (56%) in GutGard treated group whereas in placebo treated group only 2 subjects (4%) showed negative response; the difference between the groups was statistically significant. On day 60, the results of 13C-UBT were negative in 24 (48%) in GutGard treated group and the difference between the groups was statistically significant. The findings suggest GutGard is effective in the management of H. pylori.